...in mouse models of other types of palmoplantar keratoderma and other diseases involving hyperproliferative keratinocytes. Evgen Pharma plc...

...tamoxifen or a third-generation aromatase inhibitor in about 60 patients with evidence of disease progression. Evgen Pharma plc...
...PFS), overall survival (OS) and time to next treatment Status: Phase II started Milestone: NA Julian Zhu SFX-01 sulforaphane Evgen Pharma plc...

...for up to 28 days plus nimodipine and has enrolled 26 of 90 planned patients. Evgen Pharma plc...
...and incidence of delayed cerebral ischemia Status: Phase II ongoing Milestone: Phase II data (1H18) Julian Zhu SFX-01 sulforaphane Evgen Pharma plc...

...with topical vehicle. Next steps could include testing sulforaphane in other models of pachyonychia congenita. Evgen Pharma plc...

...90 patients. SFX-01 is administered as capsules or as a suspension via a nasogastric tube. Evgen Pharma plc...

...for publication. Spanish National Research Council , Madrid, Spain University of Seville , Seville, Spain Evgen Pharma plc...

...Anterios Inc. 3/31/15 $50.7M Ph II RainDance Technologies Inc. 2/27/15 Up to $60M Mkt (tools) Evgen Pharma plc...

...Inc. 2/2/15 $76M Ph III HTG Molecular Diagnostics Inc. 12/30/14 Up to $60M Mkt (diagnostic) Evgen Pharma plc...

...12/22/14 Up to $69M Mkt (diagnostic) Ascendis Pharma A/S 12/18/14 Up to $86.3M Ph II Evgen Pharma plc...